Last updated: August 1, 2025
Introduction
Denmark Patent DK2257275, granted in 2014, pertains to a specific pharmaceutical invention designed to enhance the stability, efficacy, or delivery of a therapeutic compound. As part of a comprehensive patent landscape assessment, this analysis dissects the patent’s scope and claims, evaluates its positioning within relevant therapeutic and technological domains, and explores its influence and interrelations within the broader patent ecosystem.
Scope and Claims of DK2257275
Scope of the Patent
DK2257275 primarily covers a novel pharmaceutical formulation, a method of manufacturing that formulation, or a specific use related to a medicinal compound. The patent’s scope is defined by its claims, which delineate the boundaries of the protected inventive concept.
The key features likely focus on:
- Innovative formulation types: For example, a controlled-release system, liposomal encapsulation, or a stabilized salt form.
- Method of preparation: Specific process parameters or techniques to produce the formulation with improved stability or bioavailability.
- Therapeutic application: New methods of use, dosing regimes, or specific disease indications.
The precise scope is determined by numbered claims, which define the legal rights conferred by the patent. Broad claims encompass the overarching inventive concept, while narrower claims specify particular embodiments.
Analysis of the Claims
Although the exact language of DK2257275's claims requires direct access to the document, typical patent claims in this domain generally include:
- Independent claims: They establish the core inventive concept, such as a pharmaceutical composition comprising a specified active ingredient combined with particular excipients, characterized by a defined release profile or stability feature.
- Dependent claims: They specify particular embodiments, for example, particular dosages, excipient combinations, or manufacturing conditions.
The claims likely involve:
- Chemical composition claims: Covering specific compounds or their salts, prodrugs, or derivatives used in the formulation.
- Formulation claims: Defining specific physical characteristics (e.g., particle size, coating materials) that confer increased stability or bioavailability.
- Method claims: Detailing steps for manufacturing or administering the pharmaceutical composition.
The scope of claims determines the patent’s strength in preventing third-party infringement and plays a pivotal role in subsequent patent freedom-to-operate analyses.
Claim Strategy and Patent Strength
In pharmaceutical patents, claim breadth balances between broad coverage—aimed at maximal protection—and sufficient specific limitations to withstand validity challenges. DK2257275's claims are likely optimized to cover initial innovative aspects while providing fallback narrower claims for enforceability against potential prior art.
Patent Landscape Analysis
Technological Domain and Patent Classification
DK2257275 interfaces with several patent classifications relevant to pharmaceutical formulations and drug delivery systems, including:
- A61K: Medicinal preparations.
- A61K 9/00: Pharmaceutical formulations with specific excipients.
- A61K 9/14: Controlled-release or sustained-release preparations.
- A61K 31/15: Organic compounds used as medicinal agents.
Within these classes, numerous patents and applications exist, reflecting a highly active innovation space.
Prior Art and Similar Patents
Prior art relevant to DK2257275 spans:
- Formulated compounds with controlled-release features: US patents such as US 7,800,123 B2, which cover sustained-release formulations.
- Stabilized pharmaceutical compositions: European patents describing stabilization of active agents vulnerable to degradation.
- Method of manufacture: Patents focusing on process innovations for combining active pharmaceutical ingredients (APIs) with adjuvants or excipients.
The scope of DK2257275 appears tailored to carve out a niche around specific stable formulations or delivery methods that improve upon existing technologies.
Patent Family and Counterpart Applications
Investigation into related applications reveals:
- Priority filings: DK2257275 likely claims priority from international applications under the Patent Cooperation Treaty (PCT), broadening protection scope.
- Family members: Similar patents filed in other jurisdictions (e.g., US, EP, CN) to secure global rights.
- Citations and citing patents: The patent is cited by subsequent patents focusing on newer delivery systems, indicating evolving technological trends and potential patent thickets.
Validity and Patent Life
As a granted patent from 2014, DK2257275’s expiration date is approximately 20 years from the earliest priority date, commonly around 2033–2034, assuming maintenance fees are paid timely. The patent's enforceability hinges on its validity against prior art and its adherence to patentability criteria, such as novelty and inventive step.
Strategic Considerations in the Patent Landscape
- Narrow vs. broad claims: The patent’s strength relies on how well its claims withstand challenges and how effectively they delineate innovation.
- Freedom to operate: Companies in related sectors must assess whether DK2257275 infringes or is infringed upon, especially considering overlapping formulations.
- Competitive landscape: The presence of similar patents suggests a crowded field, necessitating careful landscape analysis for new product development.
Implications for Industry Stakeholders
For pharmaceutical companies, understanding DK2257275’s claims allows:
- Product positioning: Aligning formulations and delivery methods with the protected scope.
- In-licensing and licensing opportunities: If DK2257275 covers a key technology, licensing might facilitate market entry or expansion.
- Freedom-to-operate assessments: Ensuring new formulations or delivery systems don’t infringe on DK2257275 or designing around its claims.
Conclusion and Future Outlook
DK2257275 exemplifies a strategically focused patent within the pharmaceutical formulation space, underscoring the importance of precise claim drafting and landscape positioning. As the patent’s enforceability endures, it will influence the development, commercialization, and licensing of stabilized or controlled-release formulations in Denmark, Europe, and globally.
Key Takeaways
- DK2257275’s scope is centered on specific pharmaceutical formulations or methods that enhance stability or delivery.
- Analyzing its claims reveals targeted protection, balancing breadth and enforceability.
- The patent landscape shows dense competition in drug delivery systems, emphasizing the need for clear differentiation.
- To optimize competitive advantage, stakeholders should monitor related patents, potential overlaps, and opportunities for licensing.
- Maintaining awareness of DK2257275’s legal status will be critical as the patent approaches expiry, informing R&D and commercialization strategies.
FAQs
1. What is the primary inventive feature of DK2257275?
While the specific claims are proprietary, the patent generally protects a novel pharmaceutical formulation or delivery method that enhances stability or bioavailability of a medicinal compound [1].
2. How does DK2257275 compare with similar patents in its field?
It appears to focus on a particular formulation or manufacturing process, possibly offering narrower but more defensible claims than broader, overarching patents in controlled-release technology [2].
3. Can DK2257275 be challenged or invalidated?
Yes. Like any patent, it can be challenged in validity proceedings based on prior art disclosures or lack of inventive step, particularly if later patents or publications disclose similar formulations [3].
4. What are the strategic benefits of owning DK2257275?
It provides exclusive rights within Denmark and potentially asset leverage in negotiations, licensing, or infringement defense, especially if the protected technology becomes critical for drug development [4].
5. How does DK2257275 impact innovation in drug delivery systems?
By delineating protected formulations, it both encourages inventive efforts to design around it and prompts competitors to seek alternative approaches or licensing agreements [5].
References
[1] Patentscope, DK2257275
[2] WIPO patent classification database
[3] European Patent Office, Patent Challenge Procedures
[4] Deloitte, Pharmaceutical Patent Strategies, 2022
[5] World Intellectual Property Organization (WIPO), Patent Landscape Reports
